GlassScriptPhysician profile
Jack F Jacoub
NPI 1528016318
$8,683.23
in general payments reported to CMS, 2019-2025
69 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,720 · 2020: $3,168 · 2021: $1,088 · 2022: $189 · 2023: $126 · 2024: $105 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437 · Education: $81.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.16 |
| Education | $81.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $617.90 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $551.31 | 2019-2021 | |
| Amgen INC. | $513.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $488.41 | 2019-2023 | Abilify, Opdivo |
| Janssen Biotech, INC. | $446.19 | 2019-2025 | Carvykti, Rybrevant, Darzalex |
| Novartis Pharmaceuticals Corporation | $329.38 | 2019-2020 | |
| Eisai INC. | $316.12 | 2019-2021 | |
| Pfizer INC. | $299.82 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $267.01 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $243.71 | 2019-2021 | |
| Astellas Pharma US INC | $237.85 | 2019-2024 | Xospata |
| Genentech USA, INC. | $236.07 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $225.89 | 2019-2020 | |
| Foundation Medicine, INC. | $213.69 | 2019-2021 | |
| Abbvie INC. | $187.72 | 2019-2021 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Jacoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.